Subscribe

Articles

Scalp Cooling Now Frequently Used for Preventing Chemotherapy-Induced Alopecia
By Meg Barbor, MPH
Supportive Care
TON - November 2016, Vol 9, No 6
As a result of the FDA approval of the DigniCap (Dignitana) system last year, and the growing evidence that scalp cooling is effective in preventing chemotherapy-induced alopecia, the practice is steadily becoming more widespread in the United States. Read More ›
In the Literature
In the Literature
TON - November 2016, Vol 9, No 6
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer
Read More ›
Walking Reduces Markers of Inflammation and Death in Male Smokers with Lung Cancer
By Caroline Helwick
Lung Cancer
TON - November 2016, Vol 9, No 6
If you cannot get your patients with lung cancer to stop smoking, at least encourage them to exercise. Read More ›
Noteworthy Numbers: Pancreatic Cancer
Noteworthy Numbers: Pancreatic Cancer
Noteworthy Numbers
TON - November 2016, Vol 9, No 6
With national and international organizations recognizing November as Pancreatic Cancer Awareness Month and November 13 as World Pancreatic Cancer Day, there will be countless opportunities to show support and help raise awareness of this disease. Presented here are a few statistics about this deadly form of cancer. Read More ›
Sustol, First Extended-Release 5-HT3 Approved for the Prevention of CINV
FDA Updates
Web Exclusives
On August 10, 2016, the FDA approved granisetron extended-release (Sustol; Heron Therapeutics) injection, the first extended-release 5-hydroxytryptamine (5-HT3) receptor antagonist, in combination with other antiemetic drugs in adults. Read More ›
Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma
FDA Updates
Web Exclusives
On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis) for the treatment of patients with advanced renal-cell carcinoma (RCC) who had received anti-angiogenic therapy.  Read More ›
Atezolizumab First PD-L1 Inhibitor Approved for the Treatment of Patients with Metastatic NSCLC
FDA Updates
Web Exclusives
On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy. Read More ›
ASCO 2016 Highlights
By Alice Goodman
Conference Correspondent
TON - September 2016, Vol 9, No 5
  • Novel Antibody Shows Promising Results in Gastric Cancer
  • Nivolumab Improves Outcomes in Patients with Anal Cancer
  • Brentuximab as an Alternative to Radiation Therapy
  • Adjuvant Temozolomide for Rare Brain Cancer
  • Internet-Mediated Application Improves Survival in Patients with Lung Cancer
  • Burnout Among Oncology Physician Assistants
  • Clinicians’ Perception of Risk and Quality of Life Affect Patient Outcomes
Read More ›
Fulvestrant Superior to Anastrozole in Extending Progression-Free Survival in Patients with Breast Cancer
By Sophie Granger
Breast Cancer
TON - September 2016, Vol 9, No 5

In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.

Read More ›

Page 191 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.